Bio-Rad Laboratories (BIO) AI Stock Analysis

• Market Cap: $8.02B
• Dividend Yield: N/A
• Average Volume (3M): 305.74K
• Price to Earnings (P/E): 25.0
• Beta (1Y): 0.80
• Revenue Growth: -0.33%
• EPS Growth: N/A
• Country: US
• Employees: 7,700
• Sector: Healthcare
• Sector Strength: 48
• Industry: Medical - Devices
• EPS (TTM): 2.61
• Shares Outstanding: 21,992,308
• 10 Day Avg. Volume: 237,212
• 30 Day Avg. Volume: 305,744
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.82
• Enterprise Value/Revenue: 2.58
• Enterprise Value/Gross Profit: 4.89
• Enterprise Value/Ebitda: 9.62
• 1Y Price Target: $333.00
• Price Target Upside: 13.71% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 69 Neutral
• Price Target: $326.00 ▲(11.32% Upside)

Bio-Rad Laboratories is showing positive momentum and recovery signs in financial performance, supported by strategic acquisitions and product advancements. However, challenges in profitability and regional revenue stability, particularly in China, pose risks. The stock is fairly valued, with no dividend yield to attract income investors.

Positive Factors

Product Performance

Process chromatography grew mid-teens percentage in the quarter, and management was constructive on consumables overall.

Negative Factors

Financial Performance

Forecasts for Bio-Rad's revenue and adjusted EBITDA have been reduced, reflecting a less optimistic outlook.

Growth Outlook

Bio-Rad Laboratories is expected to experience lower growth in their Life Sciences segment due to recent US policy changes and uncertainty around NIH funding.

Bio-Rad Laboratories Business Overview & Revenue Model

Company Description

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

How the Company Makes Money

Bio-Rad generates revenue through the sale of a diverse portfolio of products primarily in the life sciences and clinical diagnostics markets. The Life Science segment contributes significantly to revenue through the sale of reagents, instruments, and consumables utilized in research and drug development. Key revenue streams include products for protein purification, gene expression analysis, and cellular biology. In the Clinical Diagnostics segment, the company earns revenue from diagnostic tests and assays that aid in disease detection and management, including immunology, blood typing, and infectious disease testing. Additionally, Bio-Rad has established partnerships with various healthcare organizations and research institutions, which help expand its market reach and drive sales. The company also benefits from recurring revenue through consumables and maintenance contracts tied to its instruments, creating a stable income stream.

Bio-Rad Laboratories Financial Statement Overview

Summary

Bio-Rad Laboratories shows signs of recovery with improvements in profitability and cash flow generation. The company maintains a strong balance sheet with low leverage, providing a stable financial foundation. However, the company needs to focus on sustaining revenue growth and enhancing profitability to achieve industry-leading performance.

Income Statement

Bio-Rad Laboratories has shown a mixed performance in its income statement. The TTM (Trailing-Twelve-Months) data indicates a gross profit margin of 52.8%, which is healthy, but there is a significant decline in net profit margin to 12.5% from previous negative margins, indicating improvement but still below industry standards. Revenue growth has been inconsistent, with a recent positive trend of 51.6% in TTM, suggesting recovery. EBIT and EBITDA margins have improved to 19.5% and 26.9% respectively, showing better operational efficiency.

Balance Sheet

The balance sheet of Bio-Rad Laboratories reflects a stable financial position with a debt-to-equity ratio of 0.20, indicating low leverage and financial risk. The return on equity (ROE) has improved to 4.6% in TTM, recovering from negative values, but still needs enhancement. The equity ratio stands at a solid 69.8%, showcasing a strong equity base relative to total assets.

Cash Flow

Cash flow analysis reveals a positive trend with a free cash flow growth rate of 4.6% in TTM, indicating better cash generation. The operating cash flow to net income ratio is nearly 1, suggesting efficient conversion of income into cash. The free cash flow to net income ratio is 65.1%, reflecting a good level of cash flow relative to profits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.55B	2.57B	2.67B	2.80B	2.92B	2.55B
Gross Profit	1.35B	1.38B	1.43B	1.57B	1.64B	1.44B
EBITDA	686.19M	-2.14B	-654.80M	-4.49B	5.59B	5.08B
Net Income	319.17M	-1.84B	-637.32M	-3.63B	4.25B	3.81B
Balance Sheet
Total Assets	10.21B	9.36B	12.30B	13.50B	17.80B	12.97B
Cash, Cash Equivalents and Short-Term Investments	1.37B	1.66B	1.61B	1.79B	869.92M	991.12M
Total Debt	1.41B	1.37B	1.41B	1.39B	223.38M	225.74M
Total Liabilities	3.09B	2.79B	3.56B	3.89B	4.11B	3.09B
Stockholders Equity	7.13B	6.57B	8.74B	9.62B	13.69B	9.88B
Cash Flow
Free Cash Flow	347.52M	266.20M	218.26M	80.29M	535.72M	476.41M
Operating Cash Flow	534.16M	455.20M	374.94M	194.45M	669.46M	584.97M
Investing Cash Flow	-198.68M	-160.20M	20.21M	-1.21B	-797.38M	-69.89M
Financing Cash Flow	-356.23M	-218.80M	-425.65M	973.58M	-55.43M	-523.04M

Bio-Rad Laboratories Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 292.84
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIO, the sentiment is Positive. The current price of 292.84 is above the 20-day moving average (MA) of 280.27, above the 50-day MA of 260.72, and above the 200-day MA of 280.35, indicating a bullish trend. The MACD of 10.80 indicates Negative momentum. The RSI at 61.66 is Neutral, neither overbought nor oversold. The STOCH value of 55.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BIO.

Bio-Rad Laboratories Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BIO	69 Neutral	$8.02B	24.96	4.59%	―	-0.33%	―
IRTC	66 Neutral	$5.40B	―	-91.13%	―	22.37%	31.14%
ITGR	65 Neutral	$3.80B	47.73	5.15%	―	7.21%	-23.29%
LIVN	61 Neutral	$3.09B	30.62	-17.87%	―	8.57%	-1154.64%
BRKR	59 Neutral	$5.17B	65.01	4.43%	0.60%	10.36%	-78.26%
INSP	58 Neutral	$2.71B	53.47	8.07%	―	22.05%	785.52%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%

Bio-Rad Laboratories Corporate Events

Bio-Rad Hosts Webinar on Digital PCR Advancements

On August 26, 2025, Bio-Rad Laboratories hosted an informational webinar on its Droplet Digital PCR product portfolio, highlighting the technology’s precision and scalability. The event, led by company executives, aimed to showcase Bio-Rad’s leadership in digital PCR and its potential to drive future growth by transitioning customers from traditional PCR methods to its advanced digital solutions.

Bio-Rad Reports Q2 2025 Financial Results

Bio-Rad Laboratories announced its financial results for the second quarter of 2025, reporting a 2.1% increase in total net sales compared to the same period in 2024, driven by higher sales in process chromatography products. The company completed the acquisition of Stilla Technologies, enhancing its Droplet Digital PCR offerings. Despite a slight decline in gross margin and income from operations, Bio-Rad recognized a significant net income due to changes in the fair market value of its investment in Sartorius AG. The company updated its full-year 2025 financial outlook, expecting non-GAAP, currency-neutral revenue growth of approximately 0 to 1.0 percent.

Bio-Rad Laboratories Appoints New Executive VP for Growth

Bio-Rad Laboratories announced the appointment of Rajat Mehta as Executive Vice President, Global Commercial Operations, effective August 4, 2025, following the retirement of Mike Crowley after a 26-year tenure. Mehta brings extensive leadership experience from Labcorp and Thermo Fisher Scientific, and his appointment is expected to drive Bio-Rad’s global commercial strategy and long-term growth, enhancing its position in the life science and clinical diagnostics markets.

Bio-Rad Completes Acquisition of Stilla Technologies

Bio-Rad Laboratories, Inc. announced on February 13, 2025, that it had entered into a binding offer to acquire all equity interests of Stilla Technologies, a French corporation. The acquisition was completed by an affiliate of Bio-Rad on June 30, 2025, marking a significant expansion of the company’s operations.